Global Human Coagulation Factor VIII Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Human Coagulation Factor VIII market size was valued at US$ 11880 million in 2024 and is forecast to a readjusted size of USD 17970 million by 2031 with a CAGR of 6.2% during review period.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
Market Drivers:
The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.
Market Challenges:
Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.
This report is a detailed and comprehensive analysis for global Human Coagulation Factor VIII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Coagulation Factor VIII market size and forecasts, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
Global Human Coagulation Factor VIII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
Global Human Coagulation Factor VIII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
Global Human Coagulation Factor VIII market shares of main players, shipments in revenue ($ Million), sales quantity (K Bottles), and ASP (USD/Bottle), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Coagulation Factor VIII
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Human Coagulation Factor VIII market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Market segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
Major players covered
Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
SinoCellTech
Taibang Bio
Huarun Boya
Shuanglin Bio
Yuandashuyang
Weiguang Bio
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Coagulation Factor VIII product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Coagulation Factor VIII, with price, sales quantity, revenue, and global market share of Human Coagulation Factor VIII from 2020 to 2025.
Chapter 3, the Human Coagulation Factor VIII competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Coagulation Factor VIII breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Coagulation Factor VIII market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Coagulation Factor VIII.
Chapter 14 and 15, to describe Human Coagulation Factor VIII sales channel, distributors, customers, research findings and conclusion.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
Market Drivers:
The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.
Market Challenges:
Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.
This report is a detailed and comprehensive analysis for global Human Coagulation Factor VIII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Coagulation Factor VIII market size and forecasts, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
Global Human Coagulation Factor VIII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
Global Human Coagulation Factor VIII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
Global Human Coagulation Factor VIII market shares of main players, shipments in revenue ($ Million), sales quantity (K Bottles), and ASP (USD/Bottle), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Coagulation Factor VIII
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Human Coagulation Factor VIII market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Market segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
Major players covered
Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
SinoCellTech
Taibang Bio
Huarun Boya
Shuanglin Bio
Yuandashuyang
Weiguang Bio
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Coagulation Factor VIII product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Coagulation Factor VIII, with price, sales quantity, revenue, and global market share of Human Coagulation Factor VIII from 2020 to 2025.
Chapter 3, the Human Coagulation Factor VIII competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Coagulation Factor VIII breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Coagulation Factor VIII market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Coagulation Factor VIII.
Chapter 14 and 15, to describe Human Coagulation Factor VIII sales channel, distributors, customers, research findings and conclusion.
Table of Contents
143 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Human Coagulation Factor VIII by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
